A Cohort Study (Risk Prediction of HCC in Patients With Chronic Liver Disease)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Evaluating the effectiveness of standardized HCC risk stratification management in improving early diagnosis rates in patients with chronic liver disease
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 75 lat
- •Przewlekłe zapalenie wątroby B (dodatni test na antygen HBsAg przez co najmniej 6 miesięcy)
- •Przewlekłe zapalenie wątroby C
- •Rodzinny przypadek raka wątroby (u rodzica, dziecka lub rodzeństwa)
- •Stwierdzona marskość wątroby (na podstawie biopsji, badania elastografii, badań obrazowych lub testów laboratoryjnych)
- •Otyłościowa choroba wątroby z włóknieniem wątroby (stopień F3 lub wyższy)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 15, 2026
- Sex
- No restrictions
Locations (1)
The Third People's Hospital of Shenzhen
Shenzhen, China
Trial contact
Dongmei Gou, Dr
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.